Making the discoveries that defeat cancer

  • Home »
  • Research »
  • Repository

  • Administrators Login

  • Repository Homepage
  • About the Repository
  • Browse the Repository
  • Search the Repository
  • Contribute an Article
  • Missing Publications
  • Repository Help

Ensuring the right PET scan for the right patient

Tools
- Tools
+ Tools

Spiro, S. G., Buscombe, J., Cook, G., Eisen, T., Gleeson, F., O'Brien, M., Peake, M. D., Rowell, N. P., Seymour, R. (2008) Ensuring the right PET scan for the right patient. LUNG CANCER, 59 (1). pp. 48-56. ISSN 0169-5002

Full text not available from this repository.

Abstract

Guidelines issued by the National Institute for Clinical Excellence (NICE) in the England and Wales recommend that rapid access to F-18-deoxyglucose positron emission tomography (FDG-PET) is made available to all appropriate patients with non-small-cell lung cancer (NSCLC). The clinical evidence for the benefits of PET scanning in NSCLC is substantial, showing that PET has high accuracy, sensitivity and specificity for disease staging, as well as pre-therapeutic assessment in candidates for surgery and radical radiotherapy. Moreover, PET scanning can provide important information to assist in radiotherapy treatment planning, and has also been shown to correlate with responses to treatment and overall outcomes. If the government cancer waiting time targets are to be met, rapid referral from primary to secondary healthcare is essential, as is early diagnostic referral within secondary and tertiary care for techniques such as PET. Studies are also required to explore new areas in which PET may be of benefit, such as surveillance studies in high-risk patients to allow early diagnosis and optimal treatment, while PET scanning to identify treatment non-responders may help optimise therapy, with benefits both for patients and healthcare resource use. Further studies are needed into other forms of lung cancer, including small-cell lung-cancer and mesothelioma. In conclusion, PET scanning has the potential to improve the diagnosis and management of lung cancer for many patients. Further studies and refinement of guidelines and procedures will maximise the benefit of this important technique. (c) 2007 Published by Elsevier Ireland Ltd.

Item Type: Article
All Authors: Spiro, S. G., Buscombe, J., Cook, G., Eisen, T., Gleeson, F., O'Brien, M., Peake, M. D., Rowell, N. P., Seymour, R.
Uncontrolled Keywords: computed tomography; F-18-deoxyglucose positron emission tomography; NICE guidelines; non-small-cell lung cancer; small-cell lung cancer CELL LUNG-CANCER; POSITRON-EMISSION-TOMOGRAPHY; FDG-PET; WHOLE-BODY; PATHOLOGICAL RESPONSE; RADICAL RADIOTHERAPY; COST-EFFECTIVENESS; NORMAL-TISSUES; CT; F-18-FLUORODEOXYGLUCOSE
Research teams: Clinical Units > Department of Nuclear Medicine
Depositing User: Users 10 not found.
Date Deposited: 09 Jun 2008 10:06
Last Modified: 22 Sep 2009 11:25
URI: http://publications.icr.ac.uk/id/eprint/6345

Actions (login required)

View Item View Item
The Royal Marsden - NHS foundation trust